MedPath

Gallium-68 fibroblast activation protein inhibitor (68Ga-FAPI) positron emission tomography/computed tomography (PET/CT) versus 18F-fluorodeoxyglucose (18F-FDG) PET/CT for pancreatic cancer: A feasibility study

Not Applicable
Recruiting
Conditions
Pancreatic cancer
Cancer - Pancreatic
Registration Number
ACTRN12622000695707
Lead Sponsor
I-MED Radiology Network
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
10
Inclusion Criteria

Inclusion criteria
•Minimum of 18 years of age
•Histologically or cytologically confirmed pancreatic cancer
•Under consideration for surgical resection by a Wesley HPB surgeon
•No treatment with chemotherapy, external beam radiation, immunotherapy and/or angiogenesis inhibitors for up to four weeks prior to study PET/CT scans
•Adequate renal function (A patient’s eGFR needs to be greater than 35mL/min/1.73m2 to receive CT contrast).
•Ability to understand and willingness to sign a written informed consent document
•Willing and able to comply with the two required PET/CT scans

This patient group has been selected as they represent a group in which current imaging methods for staging/restaging presents an unmet diagnostic challenge.

Exclusion Criteria

Exclusion criteria
•Pancreatic disease too advanced for surgical resection to be considered standard care
•Concurrent malignancies, except non-melanoma skin cancers
•Pregnant or breast feeding
•Participation would delay imminent conventional treatment
•History of allergic reactions attributed to compounds of similar chemical or biologic composition to FAPI, FDG or intravenous iodinated contrast media
•Involvement in a clinical trial with an investigational agent which may reasonably interfere with the PET/CT imaging
•Uncontrolled intercurrent illness which may reasonably interfere with PET/CT imaging, including, but not limited to, active infection or inflammatory process

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath